Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-UK bribery investigation adds to Glencore's legal headaches

Thu, 05th Dec 2019 13:45

* Scope of SFO investigation is unclear

* DoJ is already investigating Glencore

* Share price down 9% to 3-year low

* Law firm plans legal action on behalf of investors
(Adds comments from sources, share price, lawsuit, dateline)

By Yadarisa Shabong, Julia Payne and Kirstin Ridley

LONDON, Dec 5 (Reuters) - The UK's Serious Fraud Office
(SFO) has launched a bribery investigation into Glencore
, adding to legal troubles that have hit the shares of
one of the world's biggest miners and commodity traders.

The SFO said on Thursday it had opened an investigaton into
suspicions of bribery in the conduct of business by the Glencore
group of companies, its officials, employees, agents and
associated persons in June. It declined to comment on the scope
of its inquiry.

The London-listed shares of Glencore, which has operations
in over 150 countries, fell 9% to 216.9 pence, their lowest
level in more than three years, knocking 2.6 billion pounds
($3.3 billion) off the company's market value.

Glencore, which was subpoenaed in July 2018 by the U.S.
Department of Justice over possible violations of the Foreign
Corrupt Practices Act relating to operations in Nigeria,
Venezuela and the Democratic Republic of Congo (DRC), said it
would cooperate with the investigation.

Two sources familiar with the matter said the SFO had
recently sought information relating to Glencore's involvement
in the DRC and its former business partner, Israeli billionaire
businessman Dan Gertler.

Reuters was unable to ascertain whether those enquiries were
part of the SFO's bribery probe.

A London-based spokesman for Gertler declined to comment.

Gertler was sanctioned by the United States in 2017 over
allegations he used his friendship with former DRC President
Joseph Kabila to secure sweetheart mining deals. He denied all
allegations of impropriety at the time.

Over the course of this year, Glencore's shares have fallen
more than 20%, pressured by broader concerns about safety and
sustainability in the DRC. Canada's regulatory authorities fined
a Glencore-controlled subsidiary last year after allegations of
inadequate financial disclosures in the DRC.

The legal difficulties have upset shareholders. Boies
Schiller Flexner, a London-based law firm, said it was mounting
a fully-funded legal action on behalf of institutional investors
against Glencore for damages that could exceed 1.0 billion
pounds.

Glencore's CEO Ivan Glasenberg told investors earlier this
week he expected to step down next year once a new management
team is in place.

The investigation is one of the most high-profile SFO probes
launched under Lisa Osofsky, a former FBI lawyer appointed
director last August, who has come under fire for abandoning
some of the agency's most prominent and lengthy probes.

The SFO dropped its investigations into aero engine maker
Rolls-Royce and drugs maker GlaxoSmithKline in
February and ended a seven-year, Libor benchmark interest rate
inquiry in February.

($1 = 0.7794 pounds)

(Additional reporting by Yadarisa Shabong in Bengaluru;
Alistair Smout, Barbara Lewis and Zandi Shabalala in London;
Editing by Jane Merriman and Elaine Hardcastle)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.